Aldeyra Therapeutics, Inc.
NASDAQ:ALDX · NASDAQ Capital Market
+$0.06 today
Vol 2.18M · Avg 2.13M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-76.5%
avg -62.0%
ROIC
-59.0%
avg -54.2%
ROA
-47.0%
avg -47.2%
Analysis
ROA is currently the strongest return metric at -47.0% versus its period average of -47.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Todd C. Brady | Chief Executive Officer, President & Director | $903,000.00 | — | 54 | $1.72M | 2.85% |
Michael Alfieri | Head of Finance and Principal Financial & Accounting Officer | $243,994.00 | — | 61 | $7,500.00 | 0.01% |
Adam Lazorchak | Director of Translational Sciences & Non-Clinical Development | — | — | — | — | — |
Laura Nichols | Operations Manager | — | — | — | — | — |
David Burke | Head of Investor Relations | — | — | — | $250,000.00 | 0.41% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$536,800.00
Sells
1
$113,713.47
Net Sentiment
+$423,086.53
Net buying
Most Active
Alfieri Michael
2 transactions
Analysis
Insiders reported 4 buys worth $536,800.00 and 1 sells worth $113,713.47 over the last 12 months. That adds up to net buying of $423,086.53. Alfieri Michael was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$787.86M
Candel Therapeutics, Inc.
NASDAQ:CADL
$448.72M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$443.22M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$348.62M
Amarin Corporation plc
NASDAQ:AMRN
$334.13M
Silence Therapeutics plc
NASDAQ:SLN
$321.19M
Cellectis S.A.
NASDAQ:CLLS
$308.78M
AC Immune S.A.
NASDAQ:ACIU
$242.73M
Genelux Corporation
NASDAQ:GNLX
$110.03M
Mereo BioPharma Group plc
NASDAQ:MREO
$50.69M
Who manages ALDX?
Aldeyra Therapeutics, Inc. (ALDX) lists 5 active executives. The top listed executive is Michael Alfieri, Head of Finance and Principal Financial & Accounting Officer.
Are ALDX insiders buying or selling?
Recent insider activity shows net buying of $73.32M.
Explore More
Continue the stock analysis
Jump to another research area for this company.